14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $4.25 $5.48 Wednesday, 1st May 2024 QURE stock ended at $4.57. This is 3.63% more than the trading day before Tuesday, 30th Apr 2024. During the day the stock fluctuated 6.31% from a day low at $4.36 to a day high of $4.64.
90 days $4.25 $6.85
52 weeks $4.25 $22.48

Historical uniQure N.V. prices

Date Open High Low Close Volume
Jul 20, 2021 $26.13 $26.97 $26.02 $26.79 288 163
Jul 19, 2021 $26.34 $26.80 $25.87 $26.26 312 400
Jul 16, 2021 $27.41 $27.41 $26.72 $26.84 271 648
Jul 15, 2021 $27.22 $27.62 $26.36 $27.08 312 087
Jul 14, 2021 $27.96 $28.09 $27.42 $27.53 386 043
Jul 13, 2021 $28.03 $28.39 $27.25 $27.75 324 523
Jul 12, 2021 $28.81 $29.18 $28.19 $28.21 157 038
Jul 09, 2021 $28.23 $29.17 $27.70 $28.81 182 743
Jul 08, 2021 $28.03 $28.69 $27.52 $28.05 369 961
Jul 07, 2021 $29.52 $29.58 $28.46 $28.46 548 543
Jul 06, 2021 $30.66 $30.71 $29.40 $29.44 269 477
Jul 02, 2021 $31.00 $31.02 $30.27 $30.50 221 080
Jul 01, 2021 $30.93 $31.46 $30.37 $31.26 220 499
Jun 30, 2021 $31.19 $31.33 $30.39 $30.80 229 217
Jun 29, 2021 $31.27 $31.65 $30.86 $31.19 219 622
Jun 28, 2021 $31.21 $32.10 $31.01 $31.24 264 246
Jun 25, 2021 $30.33 $30.96 $29.87 $30.94 550 397
Jun 24, 2021 $29.94 $30.81 $29.85 $30.11 415 775
Jun 23, 2021 $30.55 $31.38 $29.94 $29.97 534 757
Jun 22, 2021 $35.27 $35.54 $29.86 $30.53 1 501 473
Jun 21, 2021 $33.08 $33.21 $32.25 $32.84 293 859
Jun 18, 2021 $34.01 $34.93 $32.78 $32.87 1 032 124
Jun 17, 2021 $34.12 $35.64 $33.88 $34.50 394 498
Jun 16, 2021 $34.38 $35.14 $33.51 $34.44 358 867
Jun 15, 2021 $35.43 $35.51 $34.10 $34.46 405 295
Click to get the best stock tips daily for free!

About uniQure N.V.

uniQure N.V. uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phas... QURE Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT